AI Policy Wiki
Dashboard

OpenEvidence

medium confidence · updated 2026-07-18

AI medical-search company described as 'ChatGPT for doctors'; used by a majority of US physicians. Reported in July 2026 to be weighing a raise at a ~$20 billion valuation on ~$300 million annualized revenue, with separate acquisition interest.

OpenEvidence is a US company operating an AI medical-search and reference platform for physicians, described in coverage as a "ChatGPT for doctors." As of April 2026 the platform was used by roughly 65% of US doctors across about 27 million clinical encounters in a month, with roughly 650,000 active US physicians and 1.2 million international users; 60% of queries concerned clinical decision-making. The tool is free for credentialed users and ad-supported. CEO Daniel Nadler said, "We did the hardest thing in the history of American health care…We got the majority of American doctors to all voluntarily adopt a single technology platform" (Source: nbcnews.com).

Reported concerns include hallucinations, the lack of rigorous patient-impact studies, and deskilling; MaineHealth asks clinicians to refrain from entering protected health information (Source: nbcnews.com).

Snapshot

Valuation

DateValuationNotesSource
2026-07-17~$20B (considering raise of ~$200M)Separate acquisition talks with a large technology company also reportedtheinformation.com
~2026-Q1$12B ($700M raised)Sequoia, GV, Nvidia, a16z, Thrive; ~12× valuation increase in just over a yearnbcnews.com

Revenue

DateFigureNotesSource
2026-07-17~$300M annualizedDoubled in seven months; 90% gross margins reportedtheinformation.com

Relationships